SWA
RVLP

SFMG Wealth Advisors’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

SFMG Wealth Advisors’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,000
Closed -$5.6K – 278
2023
Q2 		$5.6K Hold
10,000
– – ﹤0.01% 258
2023
Q1 		$11.4K Hold
10,000
– – ﹤0.01% 264
2022
Q4 		$11.2K Hold
10,000
– – ﹤0.01% 260
2022
Q3 		$21K Hold
10,000
– – ﹤0.01% 247
2022
Q2 		$14K Buy
+10,000
New +$14.5K ﹤0.01% 273

Other funds holding RVLP

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
TAM
Titleist Asset Management San Antonio, Texas $1.49B AUM 22.27% 1-Year Est. Return

SFMG Wealth Advisors's RVLP Position: Q3 2023 in Review

SFMG Wealth Advisors sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q3 2023, closing a stake of 10,000 shares — an estimated $5.6K sold.

SFMG Wealth Advisors first reported a position in RVLP in Q2 2022 and held it in 5 quarters. The position peaked at $21K in Q3 2022. 32 funds tracked by Wall St. Rank hold RVLP as of Q3 2023.

  • SFMG Wealth Advisors reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • SFMG Wealth Advisors sold 10,000 RVL Pharmaceuticals plc Ordinary Shares shares in Q3 2023, an estimated $5.6K.
  • SFMG Wealth Advisors first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q2 2022 and held it in 5 quarters.
  • SFMG Wealth Advisors's RVL Pharmaceuticals plc Ordinary Shares position peaked at $21K in Q3 2022.
  • 32 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q3 2023.

Based on SFMG Wealth Advisors's 13F filing for Q3 2023, filed 6 Nov 2023.